Elie Dolgin
Impact in
- Aging top 2%
- Infectious Diseases top 2%
- SARS-CoV-2 and COVID-19 Research
Papers in
-
- CRISPR and Genetic Engineering 22
- Pluripotent Stem Cells Research 15
-
- Biotechnology and Related Fields 18
- Co-authors
- Brian Charlesworth (4 shared papers)Asher D. Cutter (2 shared papers)Alison Abbott (1 shared paper)Scott E. Baird (1 shared paper)Aneil F. Agrawal (1 shared paper)Michael C. Whitlock (1 shared paper)Sarah P. Otto (1 shared paper)Heidi Ledford (3 shared papers)
- Journals
- Nature (126 papers)Nature Medicine (101 papers)Nature Biotechnology (47 papers)Nature Reviews Drug Discovery (15 papers)Proceedings of the National Academy of Sciences (6 papers)
- Partner nations
- United StatesCanadaUnited Kingdom
In The Last Decade
Elie Dolgin
297 papers receiving 4.5k citations
Elie Dolgin's Hit Papers
Peers
Comparison fields: 5 of 189
- Aging 107
- Infectious Diseases 575
- Ophthalmology 214
- Epidemiology 681
- Molecular Biology 1.4k
Countries citing papers authored by Elie Dolgin
This map shows the geographic impact of Elie Dolgin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Elie Dolgin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Elie Dolgin more than expected).
Fields of papers citing papers by Elie Dolgin
This network shows the impact of papers produced by Elie Dolgin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Elie Dolgin. The network helps show where Elie Dolgin may publish in the future.
Co-authors
The 20 scholars most cited alongside Elie Dolgin, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 319 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The myopia boom Hit paper breakdown → | 2015 | 669 |
| 2 | The tangled history of mRNA vaccines Hit paper breakdown → | 2021 | 307 |
| 3 | 2013 | 171 | |
| 4 | 2007 | 155 | |
| 5 | 2016 | 103 | |
| 6 | 2008 | 100 | |
| 7 | 2018 | 100 | |
| 8 | 2017 | 92 | |
| 9 | 2006 | 89 | |
| 10 | 2021 | 84 | |
| 11 | 2020 | 76 | |
| 12 | 2021 | 65 | |
| 13 | 2021 | 60 | |
| 14 | 2018 | 56 | |
| 15 | 2022 | 51 | |
| 16 | 2021 | 47 | |
| 17 | 2014 | 46 | |
| 18 | 2021 | 46 | |
| 19 | 2010 | 44 | |
| 20 | 2008 | 43 |
About Elie Dolgin
Elie Dolgin is a scholar working on Molecular Biology, Public Health, Environmental and Occupational Health, Infectious Diseases, Physiology and Genetics, having authored 319 papers that have together received 4.6k indexed citations. Recurring topics across this work include Science, Research, and Medicine (29 papers), Biomedical Ethics and Regulation (25 papers), SARS-CoV-2 and COVID-19 Research (23 papers), CRISPR and Genetic Engineering (22 papers), CAR-T cell therapy research (19 papers), Biotechnology and Related Fields (18 papers), Health Systems, Economic Evaluations, Quality of Life (16 papers) and Pluripotent Stem Cells Research (15 papers). The work is most often cited by research in Aging (107 citations), Infectious Diseases (575 citations), Ophthalmology (214 citations), Epidemiology (681 citations) and Molecular Biology (1.4k citations). Elie Dolgin has collaborated with scholars based in United States, Canada and United Kingdom. Frequent co-authors include Brian Charlesworth, Asher D. Cutter, Alison Abbott, Scott E. Baird, Aneil F. Agrawal, Michael C. Whitlock, Sarah P. Otto, Heidi Ledford, Smriti Mallapaty and Dyani Lewis. Their work appears in journals such as Nature, Nature Medicine, Nature Biotechnology, Nature Reviews Drug Discovery and Proceedings of the National Academy of Sciences.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.